Patent classifications
A61M15/08
ARTICLES FORMED OF PULP BASE MATERIALS WITH MODULATED SCENT RELEASE
Described are articles formed of a pulp base material comprising fibers, wherein pores are formed between the fibers. A volatile composition with at least one top note component and at least one base note component at least partially fills the pores of the pulp base material. A release rate of the at least one top note component is modulated by the pulp base material, and a release rate of the at least one base note component is enhanced by the pulp base material.
USE OF INHALED NITRIC OXIDE (INO) FOR THE IMPROVEMENT OF SEVERE HYPOXEMIA
Described are methods for improving oxygen saturation in patients suffering from hypoxemia, wherein said patients are receiving a continuous flow of oxygen at 10 L/min and exhibit an initial oxygen saturation of at least about 88%, comprising administering inhaled nitric oxide to said patients in an outpatient setting. Methods for improving quality of life for a hospitalized patient, reducing patient hospitalization time, and reducing costs associated with patient hospitalization are also described.
Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder
Methods and compositions for treating mTBI, PTSD or mTBI with PTSD with psychedelic agents and N-acetylcysteine are provided. Nasal mist transducers for administration of one or more pharmaceutically active ingredients such as these as fine mist particles at preselected dosages and times are also provided.
Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder
Methods and compositions for treating mTBI, PTSD or mTBI with PTSD with psychedelic agents and N-acetylcysteine are provided. Nasal mist transducers for administration of one or more pharmaceutically active ingredients such as these as fine mist particles at preselected dosages and times are also provided.
PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING MICROBIAL INFECTIONS
In alternative embodiments, provided are products of manufacture fabricated or manufactured as medical devices such as an inhaler, an ionizer, an asthma “puffer-like” device, a nebulizer or a nasal spray device, a respirator or a ventilator, a warm or a hot air delivery device, and/or a CPAP (continuous positive air pressure) device (for example, for managing or treating sleep apnea) or equivalent, for delivering one or a combination of medications or drugs, and optionally also warm or hot air, and optionally also ionized air. Products of manufacture are used for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a microbial infection, such as bacterial and viral infections, including the common respiratory viruses such as influenza virus, respiratory syncytial virus, picornavirus, parainfluenza virus, adenovirus, rhinovirus, human metapneumovirus, hantaviruses, enterovirus, a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, products of manufacture as provided herein administer combinations, or cocktails, of a drug or drugs by inhalation, for example, by use of aerosol, mist, liquid or powder formulations for inhalation.
PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING MICROBIAL INFECTIONS
In alternative embodiments, provided are products of manufacture fabricated or manufactured as medical devices such as an inhaler, an ionizer, an asthma “puffer-like” device, a nebulizer or a nasal spray device, a respirator or a ventilator, a warm or a hot air delivery device, and/or a CPAP (continuous positive air pressure) device (for example, for managing or treating sleep apnea) or equivalent, for delivering one or a combination of medications or drugs, and optionally also warm or hot air, and optionally also ionized air. Products of manufacture are used for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a microbial infection, such as bacterial and viral infections, including the common respiratory viruses such as influenza virus, respiratory syncytial virus, picornavirus, parainfluenza virus, adenovirus, rhinovirus, human metapneumovirus, hantaviruses, enterovirus, a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, products of manufacture as provided herein administer combinations, or cocktails, of a drug or drugs by inhalation, for example, by use of aerosol, mist, liquid or powder formulations for inhalation.
COMPOSITIONS FOR IMPROVING MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) AND/OR FIBROMYALGIA (FM) AND/OR INHIBITING WORSENING OF SYMPTOMS
Described is a composition for ameliorating symptoms of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and/or fibromyalgia (FM) that has few side effects and can be easily produced. Specifically, described is a composition for ameliorating at least one symptom of fatigue, headache, body pain, impaired thinking, impaired concentration, and/or impaired activity level associated with these symptoms caused by ME/CFS and/or FM in a patient, including a hydrogen gas-containing gas as an active ingredient. Also, described herein is a method for ameliorating symptoms such as fatigue, headache, body pain, impaired thinking, impaired concentration, and/or impaired activity levels associated with these symptoms caused by ME/CFS and/or FM in a patient with ME/CFS and/or FM, including administering the composition to the patient.
COMPOSITIONS FOR IMPROVING MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) AND/OR FIBROMYALGIA (FM) AND/OR INHIBITING WORSENING OF SYMPTOMS
Described is a composition for ameliorating symptoms of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and/or fibromyalgia (FM) that has few side effects and can be easily produced. Specifically, described is a composition for ameliorating at least one symptom of fatigue, headache, body pain, impaired thinking, impaired concentration, and/or impaired activity level associated with these symptoms caused by ME/CFS and/or FM in a patient, including a hydrogen gas-containing gas as an active ingredient. Also, described herein is a method for ameliorating symptoms such as fatigue, headache, body pain, impaired thinking, impaired concentration, and/or impaired activity levels associated with these symptoms caused by ME/CFS and/or FM in a patient with ME/CFS and/or FM, including administering the composition to the patient.
SYSTEMS FOR PROVIDING AROMATHERAPY AND DEVICES INCORPORATED THEREIN FOR DIFFUSING ESSENTIAL OILS
A system for providing aromatherapy to a user is described herein. The system comprises a mobile computing device including a mobile application to control the system; a diffuser mounted to the mobile computing device, the diffuser including: a body, one or more cavities in the body, one or more heating elements positioned to provide localized heating to the one or more cavities, a processor, and one or more non-transitory computer storage mediums. The system also includes a plurality of carriers including scented material, the carriers sized and configured to reversibly fill a cavity and position scented material proximate a heating element. The non-transitory computer storage mediums are encoded with one or more computer programs that, when executed by the processor in response to instructions from the mobile computing device, instruct the heating elements to apply heat from the heating elements to activate the scented material and deliver a predetermined aromatherapy experience to the user. Corresponding methods also are disclosed.
System and Method For Utilization of Data From Remote Regulation and Monitoring of Drug Delivery
Aspects and embodiments of the present invention generally include a device for patient self-administration of a prescribed medication. The device makes available for administration the precise quantity of medication constituting a dose at times designated by a health care provider (HCP). Preferably, the device also detects and transmits information to a remote management system accessible to the HCP, including detected attempts to tamper with the device. Advantageously, HCPs may render oversight and control over the device and its use to mitigate risks associated with patients self-administering medication without in-person supervision. This control may include establishing prerequisites the patient must meet prior to a dose being made available, or remote deactivation of the device. This oversight by the HCP may include patient-specific and aggregate data analysis for optimization of treatment or evaluation of the safety and efficacy of a treatment. Furthermore, this oversight may be conducted via a web-based interface.